Thomas Rampy
Neurology · Louisville, CONPI 1588637136
Payments from drug & device makers
Across 943 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- EMD Serono, Inc.$2K
- AbbVie$1K
- Biogen$1K
- Lilly USA, LLC$918
- Pfizer$759
- plus $8K from 48 others
What the payments were for
- Speaking & faculty fees$450%
- Food & beverage$15,95898%
- Education$3052%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$231
- KESIMPTA$125
- ZEPOSIA$119
- Mavenclad$102
How this compares
$16,308 in reported general payments places this provider in the 70th percentile of 334 neurology providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 39 | $270,349 |
| GlatopaGlatiramer Acetate | 12 | $26,229 |
| Nurtec OdtRimegepant Sulfate | 13 | $14,069 |
| QuliptaAtogepant | 13 | $13,539 |
| Memantine Hcl | 36 | $3,540 |
| Rivastigmine | 12 | $2,888 |
| Gabapentin | 50 | $1,652 |
| Propranolol Hcl ErPropranolol Hcl | 21 | $1,069 |
| Duloxetine Hcl | 43 | $1,005 |
| Pregabalin | 30 | $1,001 |
| Ropinirole Hcl | 14 | $880 |
| Primidone | 27 | $852 |
| Topiramate | 14 | $688 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 15 | $416 |
| Donepezil Hcl | 24 | $302 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPanzyga, Nurtec Odt | $759 | $284,41752 claims |
| AbbVieQulipta | $1,193 | $13,53913 claims |
| Upsher-smith Laboratories LLCTopiramate | $31 | $68814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 334 neurology providers in Colorado.
Other neurology in Louisville
- William WagnerLouisville$1.5M
- Enrique AlvarezAurora$14.3M
- Rajeev KumarEnglewood$14.3M
- Tamara MillerFort Collins$7.4M
- Alison AllenBasalt$4.6M
- Adam WolffDenver$2.4M
- Kimberly WagnerColorado Springs$2.3M
- Timothy VollmerAurora$2M
- Jeffrey BennettAurora$1.9M
- Justin MoonDenver$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.